<DOC>
	<DOCNO>NCT01520818</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare glycaemic control biphasic insulin aspart ( BIAsp ) 70 and/or BIAsp 50 biphasic human insulin ( BHI ) 30 treatment .</brief_summary>
	<brief_title>Comparison Biphasic Human Insulin 30 With Biphasic Insulin Aspart Subjects With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 Type 2 diabetes Current treatment BHI 30 twice daily insulin therapy least 3 month , without combination oral hypoglycaemic agent Body mass index ( BMI ) maximum 40.0 kg/m^2 History drug alcohol dependence Impaired hepatic function Impaired renal function Cardiac disease Proliferative retinopathy Total daily insulin dose least 1.80 IU/kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>